top of page

PHARMACEUTICALS

FOCUSED ON AI

& NOVEL DRUG

ALTERNATIVES

LEADERS

IN DRUG

DESIGN

OUR PARTNERS

CPS.png
Wuxi.PNG
output-onlinepngtools_edited.png
biomea.PNG
Charles-River.png
insilico.png

At A2A Pharmaceuticals, our mission is to leverage proprietary computational systems, including A.I., to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.

A2A TACC3 PROGRAM
Clinical Progress in
Womens Cancers

May 27, 2025 -A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st in Class/1st in human program , today announced progress in Phase 1, dose escalation for ovarian, triple negative and endometrial cancer patients.

 

Significant (22% average over approximately 2 months) tumor reduction in 67% of the 4b (BID) cohort patients was observed. This is at 160mg ,which is less than 1/3 of what we project to be to be the maximum tolerated dose as predicted by a very wide therapeutic index in pre-clinical studies. With no dose limiting toxicity and benign safety profile observed thus far, we are now at 240mg.We plan to initiate dose expansion and add prostate, gastric, sarcoma and patients with brain metastasis this summer.

 

While our primary focus is on mono-therapy, where we saw preclinical regressions in the above indications with PDX and organoid validation, we have seen strong synergy with chemotherapy and targeted therapies like Enehrtu and anti Pd-1 and Trop2 ADC's in preclinical models as well.

Significant Achievements to Date

1st patient dosed in ovarian, endometrial and triple negative breast cancer clinical trial

IPO for A2A Spinoff Company Biomea Fusion

Awarded Johnson & Johnson Innovation and Janssen Research & Development's Artificial Intelligence for Drug Discovery Quickfire Challenge.

50-50 Biomea JV Formation for Taking A2A's MLL-Menin program into into the clinic

2025

TACC3 Program - Stable disease and reductions in tumor sizes for ovarian and endometrial cancer patients achieved

2018

2023

IND for TACC3 program successfully filed with the FDA

2021

Raised a Total of $8M in Financing for A2A

2019

Revenue generating pilot projects for multiple larger pharmaceutical companies completed

2017

Seed funding through SOSV and incubation at IndieBio.

A2A_pipeline_may_2025.jpf

TECHNOLOGY

Sculpt.png
bottom of page